Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572013 · ClinicalTrials.gov registry record · Phase 1
Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma
A Phase 1 study of Lymphoma, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00572013 is a Phase 1 study of Lymphoma that has completed, run by University of Nebraska. The registered enrollment target is 32 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00572013, a Phase 1 study of Lymphoma, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the response rate, complete and partial, of patients with indolent lymphoma receiving Rituxan and BEAM with autologous stem cell transplant.
Conditions Studied
Interventions
- PROCEDURE Autologous stem cell transplant
- DRUG Rituxan
- DRUG BEAM
Study Locations (1)
Nebraska
- University of Nebraska Medical Center, Section of Oncology/Hematology - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 1998-05-12 |
| Est. Completion | 2009-09-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00572013
The ClinicalTrials.gov registry entry for NCT00572013 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Autologous stem cell transplant is the first listed.
NCT00572013 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT00572013 about?
NCT00572013 is a clinical study titled "Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma". To determine the response rate, complete and partial, of patients with indolent lymphoma receiving Rituxan and BEAM with autologous stem cell transplant.
What is the current status of trial NCT00572013?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 1998-05-12. Estimated completion is 2009-09-18.
What conditions does trial NCT00572013 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00572013?
The interventions under investigation include: Autologous stem cell transplant (PROCEDURE), Rituxan (DRUG), BEAM (DRUG).
Who is sponsoring clinical trial NCT00572013?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00572013 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.